Performance of PCR/electrospray ionization-mass spectrometry on whole blood for detection of bloodstream microorganisms in patients with suspected sepsisDivision of Critical Care, NIHR Biomedical Research Centre at University of College London Hospitals NHS Foundation Trust, London, United Kingdom.
Molecular Infectious Diseases, med fusion/Quest Diagnostics, Lewisville, Texas, USA.
AthoGen Testing, Carlsbad, California, USA.
Department of Emergency Medicine, University of Alabama School of Medicine, Birmingham, Alabama, USA.
University of Washington, Seattle, Washington, USA.
University of Arizona, Maricopa Medical Center, Phoenix, Arizona, USA.
AthoGen Testing, Carlsbad, California, USA.
Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
Department of Emergency Medicine, Olive View-UCLA Medical Center, Sylmar, California, USA.
eStudySite, Sharp Chula Vista, San Diego, California, USA.
Department of Emergency Medicine, New York Methodist Hospital, New York, New York, USA.
Baylor College of Medicine, Houston, Texas, USA.
Department of Emergency Medicine and Surgery, Henry Ford Hospital, Detroit, Michigan, USA; Department of Surgery, Henry Ford Hospital, Detroit, Michigan, USA.
Beaumont Health, Royal Oak and Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA.
Department of Emergency Medicine, Truman Medical Center, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Division of Medical Microbiology, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Show others and affiliations
2020 (English)In: Journal of Clinical Microbiology, ISSN 0095-1137, E-ISSN 1098-660X, Vol. 58, no 9, p. e01860-19Article in journal (Refereed) Published
Abstract [en]
Blood culture (BC) often fails to detect bloodstream microorganisms in sepsis. However, molecular diagnostics hold great potential. The molecular method PCR/electrospray ionization-mass spectrometry (PCR/ESI-MS) can detect DNA from hundreds of different microorganisms in whole blood. The aim of the present study was to evaluate the performance of this method in a multicenter study including 16 teaching hospitals in the USA (n=13) and Europe (n=3). First, on 2,754 contrived whole blood samples, with or without spiked microorganisms, PCR/ESI-MS produced 99.1% true positive and 97.2% true negative results. Secondly, among 1,460 patients with suspected sepsis (sepsis-2 definition), BC and PCR/ESI-MS on whole blood were positive in 14.6% and 25.6% of cases, respectively, with the following result combinations: BC+/PCR/ESI-MS-, 4.3%; BC+/PCR/ESI-MS+, 10.3%; BC-/PCR/ESI-MS+, 15.3%; and BC-/PCR/ESI-MS-, 70.1%. Compared with BC, PCR/ESI-MS showed the following sensitivities (coagulase-negative staphylococci not included): Gram-positive bacteria, 58%; Gram-negative bacteria, 78%; and Candida species, 83%. The specificities were > 94% for all individual species. Patients treated with prior antimicrobial medications (n=603) had significantly increased PCR/ESI-MS positivity rates compared with patients without prior antimicrobial treatment, 31% vs 22% (p<0.0001), with pronounced differences for Gram-negative bacteria and Candida species. In conclusion, PCR/ESI-MS showed excellent performance on contrived samples. On clinical samples, it showed high specificities, moderately high sensitivities for Gram-negative bacteria and Candida species, and elevated positivity rates during antimicrobial treatment. These promising results encourage further development of molecular diagnostics on whole blood for detection of bloodstream microorganisms in sepsis.
Place, publisher, year, edition, pages
American Society for Microbiology , 2020. Vol. 58, no 9, p. e01860-19
Keywords [en]
Sepsis, bacteremia, direct detection, PCR/ESI-MS
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-84767DOI: 10.1128/JCM.01860-19ISI: 000575116900045PubMedID: 32641399Scopus ID: 2-s2.0-85089922341OAI: oai:DiVA.org:oru-84767DiVA, id: diva2:1463833
Note
Funding Agencies:
Ibis Biosciences, a division of Abbott
Abbott Laboratories
Cepheid
ContraFect
Nabriva Therapeutics AG
Lajolla Pharmaceuticals
Alere Corporation
Spectral Diagnostics
Ferring Pharmaceuticals
Inflammix
VICTASm
Sanofi Pasteur Inc.
Curetis GmbH
Pfizer
Merck & Company
Cidara Therapeutics Inc.
Shire
Aridis Pharmaceuticals Inc.
Epigenomics Inc.
Roche Holding Genentech
Finch Therapeutics
Seres Therapeutics Inc.
Diasorin Molecular
Janssen Research and Development
NeuMoDx Molecular
Iterum Therapeutics International
2020-09-032020-09-032025-04-01Bibliographically approved